Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. The company is headquartered in Waltham, Massachusetts and currently employs 1,778 full-time employees. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
Follow-Up Questions
Who is the CEO of Repligen Corp?
Mr. Olivier Loeillot is the President of Repligen Corp, joining the firm since 2023.
What is the price performance of RGEN stock?
The current price of RGEN is $146.93, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Repligen Corp?
Repligen Corp belongs to Life Sciences Tools & Services industry and the sector is Health Care
What is Repligen Corp market cap?
Repligen Corp's current market cap is $8.2B
Is Repligen Corp a buy, sell, or hold?
According to wall street analysts, 21 analysts have made analyst ratings for Repligen Corp, including 7 strong buy, 15 buy, 6 hold, 0 sell, and 7 strong sell
